Equity Profile

ARQT

Arcutis Biotherapeutics, Inc.

Health CareBiotechnology$3.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) operates in the biotechnology sector, focusing on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding market demand for Arcutis' products and overall business expansion.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) operates in the biotechnology sector, focusing on developing innovative treatments for skin diseases. With a market cap of $3 billion, the company is positioned to address significant unmet needs in dermatology, making its performance relevant to investors interested in health care advancements.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, which was significantly below the expected -$0.02. Despite the miss, the stock saw a modest increase of 3.20% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Arcutis this quarter are cautious, especially after the last earnings miss. Investors will be watching closely for any signs of improvement in profitability and revenue.

Bull Case

If Arcutis can demonstrate a turnaround in EPS and show strong revenue growth, it could significantly boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, especially in profitability metrics, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's -$0.09?

The EPS figure will be critical in assessing whether the company is on a path to profitability or continuing to struggle.

What insights can management provide on revenue growth and product demand?

Understanding revenue trends will help gauge market acceptance of Arcutis' products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly focused on short-term EPS misses and not considering the long-term potential of Arcutis' product pipeline, which could drive future growth.

Supporting Evidence

The options market is pricing a significant move, suggesting that investors expect a more substantial outcome than historical trends.

Arcutis has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

Key Risk

If the EPS comes in better than expected, it could shift the narrative around the company's profitability.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around whether Arcutis can turn around its financial performance after a disappointing previous quarter.

Bull Confirmed If

Achieving an EPS of -$0.05 or better would signal a positive shift in profitability.

Bear Confirmed If

An EPS worse than -$0.10 would confirm ongoing struggles and likely lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential movement in the stock, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests the stock could rise by about 2.7%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, reflecting ongoing uncertainty in the market.

Miss

If the company misses expectations, history suggests a potential decline of around 3.2%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product launches or regulatory approvals.
2Management's commentary on market demand for existing products.
3Insights into cost management and operational efficiency.
4Guidance on future revenue expectations.
5Responses to competitive pressures in the dermatology market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) operates in the biotechnology sector, focusing on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth is crucial for understanding market demand for Arcutis' products and overall business expansion.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, which was significantly below the expected -$0.02. Despite the miss, the stock saw a modest increase of 3.20% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Arcutis this quarter are cautious, especially after the last earnings miss. Investors will be watching closely for any signs of improvement in profitability and revenue.

Bull Case

If Arcutis can demonstrate a turnaround in EPS and show strong revenue growth, it could significantly boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, especially in profitability metrics, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to last quarter's -$0.09?

The EPS figure will be critical in assessing whether the company is on a path to profitability or continuing to struggle.

What insights can management provide on revenue growth and product demand?

Understanding revenue trends will help gauge market acceptance of Arcutis' products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly focused on short-term EPS misses and not considering the long-term potential of Arcutis' product pipeline, which could drive future growth.

Supporting Evidence

The options market is pricing a significant move, suggesting that investors expect a more substantial outcome than historical trends.

Arcutis has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

Key Risk

If the EPS comes in better than expected, it could shift the narrative around the company's profitability.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around whether Arcutis can turn around its financial performance after a disappointing previous quarter.

Bull Confirmed If

Achieving an EPS of -$0.05 or better would signal a positive shift in profitability.

Bear Confirmed If

An EPS worse than -$0.10 would confirm ongoing struggles and likely lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a significant potential movement in the stock, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±18.4% while ARQT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests the stock could rise by about 2.7%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, reflecting ongoing uncertainty in the market.

Miss

If the company misses expectations, history suggests a potential decline of around 3.2%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product launches or regulatory approvals.
2Management's commentary on market demand for existing products.
3Insights into cost management and operational efficiency.
4Guidance on future revenue expectations.
5Responses to competitive pressures in the dermatology market.